Formestane

Formestane
Clinical data
Trade names	Lentaron, others
Synonyms	4-Hydroxyandrost-4-ene-3,17-dione
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intramuscular injection
Drug class	Aromatase inhibitor; Antiestrogen
ATC code	L02BG02 (WHO) ;
Identifiers
	IUPAC name (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione;
CAS Number	566-48-3 ;
PubChem CID	11273;
ChemSpider	10799 ;
UNII	PUB9T8T355;
KEGG	D07260 ;
ChEBI	CHEBI:75172 ;
ChEMBL	CHEMBL132530 ;
ECHA InfoCard	100.153.838
Chemical and physical data
Formula	C19H26O3
Molar mass	302.408 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4;
	InChI InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1 ; Key:OSVMTWJCGUFAOD-KZQROQTASA-N ;
(what is this?) (verify)

Formestane, formerly sold under the brand name Lentaron among others, is a steroidal, selective aromatase inhibitor which is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women.^[1] The drug is not active orally, and was available only as an intramuscular depot injection. Formestane was not approved by the United States FDA and the injectable form that was used in Europe in the past has been withdrawn from the market.^[2] Formestane is an analogue of androstenedione.

Formestane is often used to suppress the production of estrogens from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a weak aromatase inhibitor.

References

↑ Pérez Carrión R, Alberola Candel V, Calabresi F, et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457.
↑ https://pubchem.ncbi.nlm.nih.gov/compound/formestane#section=Top

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid7873457-1] Pérez Carrión R, Alberola Candel V, Calabresi F, et al. (1994). "Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer". Ann. Oncol. 5 Suppl 7: S19–24. PMID 7873457.

[2] ttps://pubchem.ncbi.nlm.nih.gov/compound/formestane#section=Top